Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Colorcon
Dow
Boehringer Ingelheim
Medtronic

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,598,376

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,598,376 protect, and when does it expire?

Patent 9,598,376 protects MEKTOVI and is included in one NDA.

This patent has seventeen patent family members in ten countries.

Summary for Patent: 9,598,376
Title:Preparation of and formulation comprising a MEK inhibitor
Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-car- boxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
Inventor(s): Krell; Christoph Max (Basel, CH), Misun; Marian (Basel, CH), Niederer; Daniel Andreas (Basel, CH), Pachinger; Werner Heinz (Basel, CH), Wolf; Marie-Christine (Basel, CH), Zimmermann; Daniel (Basel, CH), Liu; Weidong (Boulder, CO), Stengel; Peter J. (Boulder, CO), Nichols; Paul (Boulder, CO)
Assignee: Array BioPharma, Inc. (Boulder, CO) Novartis AG (Basel, CH)
Application Number:15/053,441
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,598,376

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING MELANOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,598,376

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 099630   Start Trial
Brazil 112015008623   Start Trial
Canada 2888474   Start Trial
China 104870427   Start Trial
China 109336824   Start Trial
China 109456272   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Johnson and Johnson
McKesson
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.